HIV/AIDS-Related Neuropathy – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)-related neuropathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of HIV/AIDS-related neuropathy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s HIV/AIDS-related neuropathy forecast will answer the following question:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HIV/AIDS-related neuropathy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts four HIV/AIDS-related neuropathy patient populations, as follows:

• Total prevalent cases of HIV/AIDS-related neuropathy.
• Total prevalent cases HIV/AIDS-related neuropathic pain.
• Diagnosed prevalent cases of HIV/AIDS-related neuropathy.
• Diagnosed prevalent cases of HIV/AIDS-related neuropathic pain.
• … and more (details available on request).

Note: Coverage may vary by country.